Drug Profile


Alternative Names: Aezea; Cenersen sodium; EL625; EL831; OL(1)p53

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Nebraska Medical Center
  • Developer Eleos; H. Lee Moffitt Cancer Center and Research Institute
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Myelodysplastic syndromes
  • Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in USA (IV, Infusion)
  • 01 Sep 2014 Phase-I clinical trials in Myelodysplastic syndromes in USA (IV)
  • 18 Jul 2012 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top